Spelling suggestions: "subject:"calcium channel blocker""
11 |
Time dependency in the protection from myocardial injury after myocardial ischemia and reperfusion : new insights from experimental studies with the ultrashort-acting calcium antagonist clevidipine /Segawa, Daisuke, January 2002 (has links)
Diss. (sammanfattning) Stockholm : Karol. inst., 2002. / Härtill 5 uppsatser.
|
12 |
Potential impact of breast cancer resistance protein on drug disposition during pregnancy /Zhang, Yi. January 2007 (has links)
Thesis (Ph. D.)--University of Washington, 2007. / Vita. Includes bibliographical references (leaves 98-113).
|
13 |
The actions of calcium antagonists on systemic hemodynamics, blood flow distribution and venous tone of the ratWaite, Robert Patrick January 1987 (has links)
The purpose of my study was to determine and compare the effects of three calcium antagonists on systemic hemodynamics, ECG, blood flow distribution,
tissue conductance and venous tone of the rat.
The effects of a representative drug from Spedding's (1985) three subclasses
of calcium antagonists on systemic hemodynamics, ECG, cardiac output and the distribution of blood flow were investigated by the microsphere technique in pentobarbital-anesthetized rats. The representative drugs were: I, nifedipine (12 and 35 µg/kg/min); II, verapamil (43 and 83 µg/kg/min) and III, flunarizine (174 and 275 µg/kg/min). Low and high doses were selected to give a decrease in mean arterial pressure of 10 and 20 mmHg, respectively, compared with control rats. At equal depressor levels, all the drugs similarly decreased total peripheral resistance while slightly but not significantly increasing cardiac output (CO) and stroke volume. Heart rate was decreased by verapamil and flunarizine, but increased by nifedipine. The high dose of nifedipine decreased contractility as measured by dP/dt and had no effect on PR-interval, while verapamil decreased dP/dt and prolonged the PR-interval. The low dose of nifedipine and both doses of flunarizine slightly but not significantly decreased dP/dt and had no effect on PR-interval. All three drugs similarly affected the distribution of blood flow. Blood flow to lungs, liver, and heart was increased while flow to the intestine, kidneys, spleen and skin was decreased. Arterial conductances
in lungs, liver, heart and skeletal muscle were increased by the three drugs. These results show that representative drugs from the three subclasses of calcium antagonists had similar effects on the distribution of blood flow and arterial conductances but different chronotropic, dromotropic and inotropic effects.
A final set of experiments were designed to evaluate calcium antagonist actions on venous tone, as venous tone is a primary determinant of CO and the calcium antagonists generally increase CO. The effects of three calcium antagonists, verapamil, nifedipine and flunarizine on mean arterial pressure (MAP), heart rate (HR) and mean circulatory filling pressure (MCFP), an index of total body venous tone, were investigated in the. conscious rat. Infusions of all three drugs caused a dose-dependent decrease in MAP and an increase in MCFP, compared with the corresponding values in control rats. HR was decreased by verapamil and flunarizine and slightly increased by nifedipine. Further experiments investigated whether the increase in MCFP by verapamil was indirectly caused by reflex activation of the autonomic nervous system. Rats were pretreated with a continuous infusion of the ganglionic blocker hexamethonium prior to infusion of verapamil. After treatment with hexamethonium, verapamil did not increase the MCFP. In fact the highest dose of verapamil significantly decreased MCFP. The results suggest that calcium antagonists have greater dilator effects in arterioles compared to veins. It appears that any direct venodilator effects of verapamil
in conscious rats are masked due to reflex activation of the autonomic nervous system. / Medicine, Faculty of / Anesthesiology, Pharmacology and Therapeutics, Department of / Graduate
|
14 |
Planejamento e validação anti-proliferativa e anti-leishmania, de novos híbridos tri-funcionalizados unidos através do anel 1,2,3-triazol e compostos similares / Design, anti-proliferative and anti-leishmanial evaluation of new tri-functionalized hybrids linked through a 1,2,3-triazole moiety and similar compounds.Federico, Leonardo Bruno 02 December 2016 (has links)
As concepções de moduladores da dinâmica dos microtúbulos, que levam ao bloqueio do ciclo celular, e de bloqueadores de canais de cálcio tipo L (Cav), tais como o 1,4-di-hidropiridinas e análogos, que diminuem a resistência do organismo humano aos tratamentos quimioterápicos através da inibição da proteína de transmembrana P-gp, são estratégias importantes tanto para terapias antitumorais quanto para leishmanicida. Esta abordagem tem mostrado resultados interessantes na diminuição da resistência à quimioterapia em câncer chamada de MDR (do inglês Multi Drug Resistence), além de também serem uma estratégia importante para controlar a fase inicial da leishmaniose. Diante desse contexto, e baseado no estudo de Ueki 2013 e colaboradores que, a partir de estudos anteriores, os quais relatam a superexpressão das enzimas estona deacetilase (HDAC) e catepsina L (CTSL) em células tumorais, propuseram um pró-fármaco seletivo, planejado a partir de um espaçador de lisina acetilada, que garante a liberação do fármaco seletivamente nas células tumorais, trabalhamos no desenvolvimento de uma nova proposta de pró-fármaco trifuncional. Nossa proposta foi desenvolvida a partir de estudos de triagem virtual, baseados em ligantes e em estrutura, predição das propriedades farmacocinéticas e toxicológicas (ADME/Tox) e também técnicas de bioinformática para a construção de um modelo de canal de cálcio, devido à inexistência de estruturas, do mesmo, que estivessem depositadas no banco de dados de proteínas PDB (Protein Data Bank). Paralelamente, nosso grupo de síntese colaborador sintetizou, através de técnicas de \"Click Chemistry\" e reações de Mitsunobu multicomponentes, uma biblioteca de novos híbridos trifuncionais, os quais, após estudos de atividade biológica, foram avaliados (in silico) frente à estrutura da tubulina, e os compostos mais promissores desta biblioteca serviram de base para novos estudos de triagem virtual. Para a obtenção dos nossos hits, executamos 4 estratégias de triagem virtual, separadas em 2 tarefas. Ao final, selecionarmos um total 59 hits, dos quais, 9 hits apresentam promissoras atividades bloqueadoras do canal de cálcio e 65 hits apresentam promissoras atividades moduladoras da tubulina. Estes hits seguem em estágio de compra e ensaios in vitro e após comprovada a eficácia dos mesmos, estes futuramente farão parte de uma nova proposta de pró-farmaco trifuncional. / The concepts of modulating microtubule dynamics, and calcium channel L-types (CAV) blockers are important strategies for anticancer and antileishmanial therapies. Microtubule modulators that blocks the cell cycle and the calcium channel blockers, such as, 1,4-dihydropyridines and analogues, reduce the resistance of the human body to chemotherapeutic treatments by inhibiting transmembrane P-gp protein. This approach has shown interesting results in reduced resistance to chemotherapy in cancer called MDR (Multi Drug Resistance), and an important strategy for controlling the early stage of leishmaniasis. In this context, we work to develop a new proposal for trifunctional prodrug. We have based on the study of Ueki 2013 and collaborators, which, from earlier studies with reported overexpression of both deacetylase estona enzymes (HDACs) and cathepsin L (CTSL) in tumor cells, proposed a selective prodrug. We considering an acetylated lysine link/spacer, which ensures the release of the drug selectively in tumor cells, have now designed this selective prodrug. Our proposal was developed from virtual screening studies, based on ligands and structure, prediction of pharmacokinetic and toxicological properties (ADME / Tox) and also bioinformatics techniques for the construction of a calcium channel model, due to the inexistence of Structures of the same that were deposited in the database of proteins PDB (Protein Data Bank). At the same time, our collaborating synthesis group synthesized, through Click Chemistry techniques and Mitsunobu multicomponent reactions, a library of new trifunctional hybrids, which, after studies of biological activity, were evaluated (in silico) against the structure of tubulin , And the most promising compounds from this library served as the basis for further virtual screening studies. To obtain our hits, we performed 4 virtual screening strategies, separated into 2 tasks. In the end, we selected 59 hits, of which 9 hits show promising calcium channel blocking activities and 65 hits show promising tubulin modulating activities. These hits follow in vitro purchase and testing, and after proven effectiveness, they will be part of a new tri prodrug proposal.
|
15 |
Efeito da tansulosina e do nifedipino na eliminação de fragmentos após litotripsia extracorpórea por ondas de choque em pacientes com cálculos renais: estudo prospectivo, duplo-cego e randomizado / Effect of tamsulosin and nifedipine on the clearance of fragments after extracorporeal shock waves lithotripsy in patients with kidney stones - a prospective, double-blind and randomized studyVicentini, Fabio Carvalho 18 March 2011 (has links)
Introdução: A litotripsia extracorpórea por ondas de choque (LEOC) é o tratamento mais utilizado para cálculos renais de até 20 mm. O uso adjuvante de algumas drogas pode aumentar as taxas de sucesso do procedimento e diminuir a sua morbidade. Objetivos: Avaliar os efeitos da tansulosina e do nifedipino nas taxas de sucesso, nos episódios de dor e na velocidade de eliminação dos fragmentos após o tratamento de cálculos renais de 5 a 20 mm com uma única sessão de LEOC. Casuística e Métodos: Foram estudados prospectivamente 136 indivíduos portadores de cálculos renais entre 5 e 20 mm, submetidos à LEOC entre 2006 e 2009. Os pacientes foram divididos aleatoriamente em 3 grupos para receber diariamente tansulosina 0,4 mg, nifedipino retard 20mg ou placebo por até 30 dias da realização de LEOC. A analgesia foi feita com celecoxibe 200 mg. Os pacientes foram avaliados semanalmente por meio de radiografia de abdome. Foi definido como sucesso do tratamento a ausência de fragmentos maiores que 4 mm ao final de 30 dias. Os parâmetros avaliados foram: taxa de sucesso do tratamento, ocorrência de rua de cálculos, necessidade de analgésicos, intensidade de dor após a LEOC, tempo de eliminação de fragmentos, efeitos adversos da medicação e visitas ao Pronto Socorro. Resultados: Cento e onze pacientes completaram o estudo. Não houve diferenças demográficas entre os pacientes e nem em relação ao tamanho dos cálculos entre os grupos. As taxas de sucesso foram de 60,5% (23 de 38) no Grupo Tansulosina, 48,6% (17 de 35) no Grupo Nifedipino e 36,8% (14 de 38) no Grupo Placebo. (p=0,118) Entre os pacientes com cálculos de 10 a 20 mm, a taxa de sucesso foi significativamente maior nos Grupos Tansulosina (61,9%) e Nifedipino (60,0%) do que no Grupo Placebo (26,1%) (p=0,024), porém não foi significativa entre os cálculos de 5 a 9 mm (p=0,128). O Número Necessário para Tratar (NNT) da Tansulosina foi de 2,9 e o do Nifedipino foi de 3, considerando-se o uso para cálculos de 10 a 20 mm. Os pacientes que usaram nifedipino tiveram mais efeitos adversos do que os do Grupo Placebo (28,5 % x 2,6% respectivamente, p = 0,009), porém sem levar à interrupção do uso da drogas. Não houve diferença significativa entre os grupos Tansulosina x Nifedipino e Tansulosina x Placebo em relação aos efeitos adversos (p= 0,15 e p = 0,054, respectivamente). Não houve diferença entre os grupos com relação à intensidade da dor observada após o tratamento (p=0,28), ao número de comprimidos de Celecoxibe (p=0,39), ao tempo de eliminação dos fragmentos (p=0,6), à ocorrência de rua de cálculos (p=0,482) e ao número de vistas ao Pronto Socorro (p=0,175). Conclusões: O uso adjuvante de tansulosina ou de nifedipino após LEOC aumenta a taxa de sucesso para cálculos renais entre 10 e 20 mm, porém sem diminuir a intensidade da dor ou a necessidade de analgésicos após o tratamento, nem o tempo de eliminação dos fragmentos / Purpose: We evaluated the effects of the adjuvant use of tamsulosin and nifedipine after extracorporeal shock wave lithotripsy (SWL) for 5-20 mm kidney stones. Materials and Methods: We conducted a randomized double-blind trial involving 136 patients with radiopaque kidney stones between 2006 and 2009. Patients were divided into three groups to receive daily treatments of 0.4 mg tamsulosin, 20 mg nifedipine retard or placebo for up to 30 days after one session of SWL. The parameters assessed were success rate, analgesic requirements, pain intensity, time to clearance, adverse effects and occurrence of Steinstrasse. Results: The success rate was 60.5% (23 of 38) in the Tamsulosin group, 48.6% (17 of 35) in the Nifedipine group and 36.8% (14 of 38) in the Placebo group (p=0.118). For stones ranging from 10 to 20 mm, the success rates were significantly higher in the Tamsulosin (61.9%) and Nifedipine groups (60.0%) when compared with the Placebo group (26.1%) (p=0.024), but not for the 5-9 mm stones (p=0.128). The Number Needed to Treat was 2.9 for tamsulosin and 3 for nifedipine. Adverse events were more frequent in the Nifedipine than the Placebo Group (28.5% vs. 2.6%, respectively, p=0.009). There was no difference among groups with regard to stone and demographic characteristics, pain intensity, time to clearance and Steinstrasse. Conclusions: Adjuvant use of tamsulosin or nifedipine after SWL significantly increased the success rates for 10 to 20 mm renal stones and could be recommended. Both drugs had similar beneficial effects and adverse events
|
16 |
Planejamento e validação anti-proliferativa e anti-leishmania, de novos híbridos tri-funcionalizados unidos através do anel 1,2,3-triazol e compostos similares / Design, anti-proliferative and anti-leishmanial evaluation of new tri-functionalized hybrids linked through a 1,2,3-triazole moiety and similar compounds.Leonardo Bruno Federico 02 December 2016 (has links)
As concepções de moduladores da dinâmica dos microtúbulos, que levam ao bloqueio do ciclo celular, e de bloqueadores de canais de cálcio tipo L (Cav), tais como o 1,4-di-hidropiridinas e análogos, que diminuem a resistência do organismo humano aos tratamentos quimioterápicos através da inibição da proteína de transmembrana P-gp, são estratégias importantes tanto para terapias antitumorais quanto para leishmanicida. Esta abordagem tem mostrado resultados interessantes na diminuição da resistência à quimioterapia em câncer chamada de MDR (do inglês Multi Drug Resistence), além de também serem uma estratégia importante para controlar a fase inicial da leishmaniose. Diante desse contexto, e baseado no estudo de Ueki 2013 e colaboradores que, a partir de estudos anteriores, os quais relatam a superexpressão das enzimas estona deacetilase (HDAC) e catepsina L (CTSL) em células tumorais, propuseram um pró-fármaco seletivo, planejado a partir de um espaçador de lisina acetilada, que garante a liberação do fármaco seletivamente nas células tumorais, trabalhamos no desenvolvimento de uma nova proposta de pró-fármaco trifuncional. Nossa proposta foi desenvolvida a partir de estudos de triagem virtual, baseados em ligantes e em estrutura, predição das propriedades farmacocinéticas e toxicológicas (ADME/Tox) e também técnicas de bioinformática para a construção de um modelo de canal de cálcio, devido à inexistência de estruturas, do mesmo, que estivessem depositadas no banco de dados de proteínas PDB (Protein Data Bank). Paralelamente, nosso grupo de síntese colaborador sintetizou, através de técnicas de \"Click Chemistry\" e reações de Mitsunobu multicomponentes, uma biblioteca de novos híbridos trifuncionais, os quais, após estudos de atividade biológica, foram avaliados (in silico) frente à estrutura da tubulina, e os compostos mais promissores desta biblioteca serviram de base para novos estudos de triagem virtual. Para a obtenção dos nossos hits, executamos 4 estratégias de triagem virtual, separadas em 2 tarefas. Ao final, selecionarmos um total 59 hits, dos quais, 9 hits apresentam promissoras atividades bloqueadoras do canal de cálcio e 65 hits apresentam promissoras atividades moduladoras da tubulina. Estes hits seguem em estágio de compra e ensaios in vitro e após comprovada a eficácia dos mesmos, estes futuramente farão parte de uma nova proposta de pró-farmaco trifuncional. / The concepts of modulating microtubule dynamics, and calcium channel L-types (CAV) blockers are important strategies for anticancer and antileishmanial therapies. Microtubule modulators that blocks the cell cycle and the calcium channel blockers, such as, 1,4-dihydropyridines and analogues, reduce the resistance of the human body to chemotherapeutic treatments by inhibiting transmembrane P-gp protein. This approach has shown interesting results in reduced resistance to chemotherapy in cancer called MDR (Multi Drug Resistance), and an important strategy for controlling the early stage of leishmaniasis. In this context, we work to develop a new proposal for trifunctional prodrug. We have based on the study of Ueki 2013 and collaborators, which, from earlier studies with reported overexpression of both deacetylase estona enzymes (HDACs) and cathepsin L (CTSL) in tumor cells, proposed a selective prodrug. We considering an acetylated lysine link/spacer, which ensures the release of the drug selectively in tumor cells, have now designed this selective prodrug. Our proposal was developed from virtual screening studies, based on ligands and structure, prediction of pharmacokinetic and toxicological properties (ADME / Tox) and also bioinformatics techniques for the construction of a calcium channel model, due to the inexistence of Structures of the same that were deposited in the database of proteins PDB (Protein Data Bank). At the same time, our collaborating synthesis group synthesized, through Click Chemistry techniques and Mitsunobu multicomponent reactions, a library of new trifunctional hybrids, which, after studies of biological activity, were evaluated (in silico) against the structure of tubulin , And the most promising compounds from this library served as the basis for further virtual screening studies. To obtain our hits, we performed 4 virtual screening strategies, separated into 2 tasks. In the end, we selected 59 hits, of which 9 hits show promising calcium channel blocking activities and 65 hits show promising tubulin modulating activities. These hits follow in vitro purchase and testing, and after proven effectiveness, they will be part of a new tri prodrug proposal.
|
17 |
Efeito da tansulosina e do nifedipino na eliminação de fragmentos após litotripsia extracorpórea por ondas de choque em pacientes com cálculos renais: estudo prospectivo, duplo-cego e randomizado / Effect of tamsulosin and nifedipine on the clearance of fragments after extracorporeal shock waves lithotripsy in patients with kidney stones - a prospective, double-blind and randomized studyFabio Carvalho Vicentini 18 March 2011 (has links)
Introdução: A litotripsia extracorpórea por ondas de choque (LEOC) é o tratamento mais utilizado para cálculos renais de até 20 mm. O uso adjuvante de algumas drogas pode aumentar as taxas de sucesso do procedimento e diminuir a sua morbidade. Objetivos: Avaliar os efeitos da tansulosina e do nifedipino nas taxas de sucesso, nos episódios de dor e na velocidade de eliminação dos fragmentos após o tratamento de cálculos renais de 5 a 20 mm com uma única sessão de LEOC. Casuística e Métodos: Foram estudados prospectivamente 136 indivíduos portadores de cálculos renais entre 5 e 20 mm, submetidos à LEOC entre 2006 e 2009. Os pacientes foram divididos aleatoriamente em 3 grupos para receber diariamente tansulosina 0,4 mg, nifedipino retard 20mg ou placebo por até 30 dias da realização de LEOC. A analgesia foi feita com celecoxibe 200 mg. Os pacientes foram avaliados semanalmente por meio de radiografia de abdome. Foi definido como sucesso do tratamento a ausência de fragmentos maiores que 4 mm ao final de 30 dias. Os parâmetros avaliados foram: taxa de sucesso do tratamento, ocorrência de rua de cálculos, necessidade de analgésicos, intensidade de dor após a LEOC, tempo de eliminação de fragmentos, efeitos adversos da medicação e visitas ao Pronto Socorro. Resultados: Cento e onze pacientes completaram o estudo. Não houve diferenças demográficas entre os pacientes e nem em relação ao tamanho dos cálculos entre os grupos. As taxas de sucesso foram de 60,5% (23 de 38) no Grupo Tansulosina, 48,6% (17 de 35) no Grupo Nifedipino e 36,8% (14 de 38) no Grupo Placebo. (p=0,118) Entre os pacientes com cálculos de 10 a 20 mm, a taxa de sucesso foi significativamente maior nos Grupos Tansulosina (61,9%) e Nifedipino (60,0%) do que no Grupo Placebo (26,1%) (p=0,024), porém não foi significativa entre os cálculos de 5 a 9 mm (p=0,128). O Número Necessário para Tratar (NNT) da Tansulosina foi de 2,9 e o do Nifedipino foi de 3, considerando-se o uso para cálculos de 10 a 20 mm. Os pacientes que usaram nifedipino tiveram mais efeitos adversos do que os do Grupo Placebo (28,5 % x 2,6% respectivamente, p = 0,009), porém sem levar à interrupção do uso da drogas. Não houve diferença significativa entre os grupos Tansulosina x Nifedipino e Tansulosina x Placebo em relação aos efeitos adversos (p= 0,15 e p = 0,054, respectivamente). Não houve diferença entre os grupos com relação à intensidade da dor observada após o tratamento (p=0,28), ao número de comprimidos de Celecoxibe (p=0,39), ao tempo de eliminação dos fragmentos (p=0,6), à ocorrência de rua de cálculos (p=0,482) e ao número de vistas ao Pronto Socorro (p=0,175). Conclusões: O uso adjuvante de tansulosina ou de nifedipino após LEOC aumenta a taxa de sucesso para cálculos renais entre 10 e 20 mm, porém sem diminuir a intensidade da dor ou a necessidade de analgésicos após o tratamento, nem o tempo de eliminação dos fragmentos / Purpose: We evaluated the effects of the adjuvant use of tamsulosin and nifedipine after extracorporeal shock wave lithotripsy (SWL) for 5-20 mm kidney stones. Materials and Methods: We conducted a randomized double-blind trial involving 136 patients with radiopaque kidney stones between 2006 and 2009. Patients were divided into three groups to receive daily treatments of 0.4 mg tamsulosin, 20 mg nifedipine retard or placebo for up to 30 days after one session of SWL. The parameters assessed were success rate, analgesic requirements, pain intensity, time to clearance, adverse effects and occurrence of Steinstrasse. Results: The success rate was 60.5% (23 of 38) in the Tamsulosin group, 48.6% (17 of 35) in the Nifedipine group and 36.8% (14 of 38) in the Placebo group (p=0.118). For stones ranging from 10 to 20 mm, the success rates were significantly higher in the Tamsulosin (61.9%) and Nifedipine groups (60.0%) when compared with the Placebo group (26.1%) (p=0.024), but not for the 5-9 mm stones (p=0.128). The Number Needed to Treat was 2.9 for tamsulosin and 3 for nifedipine. Adverse events were more frequent in the Nifedipine than the Placebo Group (28.5% vs. 2.6%, respectively, p=0.009). There was no difference among groups with regard to stone and demographic characteristics, pain intensity, time to clearance and Steinstrasse. Conclusions: Adjuvant use of tamsulosin or nifedipine after SWL significantly increased the success rates for 10 to 20 mm renal stones and could be recommended. Both drugs had similar beneficial effects and adverse events
|
18 |
Glutamate Excitotoxicty Activates a Novel Calcium Permeable Ion Channel in Cultured Hippocampal NeuronsDeshpande, Laxmikant Sudhir 01 January 2006 (has links)
Glutamate excitotoxicity is the predominant mechanism implicated in neuronal cell death associated with neurological disorders such as stroke, epilepsy, traumatic brain injury and ALS. Excessive stimulation of NMDA subtypes of glutamate receptors leads to protracted intracellular calcium elevations triggering calcium mediated neurotoxic mechanisms culminating in delayed neuronal cell death. In addition, glutamate excitotoxicity induces a NMDA dependent extended neuronal depolarization mediated by continuous calcium influx that correlates with delayed neuronal death. Attempts to prevent neuronal death by blocking calcium entry into the neurons using calcium channel blockers or NMDA receptor antagonists have failed to provide any beneficial effects in clinical trials. Thus, calcium continues to enter the neurons despite the presence of calcium entry blockers. This phenomenon is known as the "calcium paradox of stroke" and represents a major problem in developing effective therapies for treatment of stroke. Here employing a combination of patch clamp recordings, fluorescent calcium imaging and neuronal cell death assays in well-characterized in vivo and in vitro models of glutamate excitotoxicity, we report the discovery of a novel calcium permeable ion channel that is activated by excitotoxic glutamate injury and mediates a calcium current that is an early initiating step in causing neuronal death. Blocking this calcium permeable channel with high concentrations of Zn2+ or Gd3+ by removing extracellular calcium for a significant time period after the initial injury is effective in preventing calcium entry, apoptosis and neuronal death, thus accounting for the calcium paradox. This injury induced-calcium permeable channel provides a unique mechanism for calcium entry following stroke and offers a new target for extending the therapeutic window for preventing neuronal death after the initial excitotoxic (stroke) injury.
|
19 |
Efeitos do bloqueador de canais de cálcio amlodipina na reparação óssea em defeito cirúrgico no ramo mandibular de ratos / Effects of the calcium channel blocker amlodipine on bone healing of a surgical defect in the mandibular ramus of ratsMoraes, Rogerio Bonfante 29 September 2009 (has links)
Os anti-hipertensivos bloqueadores de canais de cálcio, por interferirem no transporte de cálcio através das membranas celulares, podem afetar muitos processos metabólicos, incluindo o metabolismo ósseo. O objetivo deste estudo foi avaliar, de forma radiográfica, histológica e bioquímica, os efeitos do bloqueador de canais de cálcio amlodipina no processo de reparo de um defeito ósseo, simulando fratura, no ramo mandibular de ratos. Foram utilizados 50 ratos machos Wistar, que foram submetidos ao mesmo procedimento cirúrgico unilateral simulando fratura mandibular, e distribuídos em dois grupos de 25 animais: grupo experimental, que receberam amlodipina, via oral, na dosagem de 0,04 mg / rato / dia, iniciando 12 dias antes do procedimento e continuando até o sacrifício; grupo controle, que permaneceu não tratado. Os animais foram sacrificados nos períodos de 1, 7, 14, 30 e 90 dias pós-operatórios. Foram realizados testes bioquímicos de fosfatase alcalina e cálcio séricos. Exame radiográfico foi obtido para mensuração da área radiolúcida do defeito ósseo. O estudo histológico compreendeu a análise descritiva do processo de reparo ósseo e a avaliação histomorfométrica da quantidade de osso neoformado. Os valores numéricos foram submetidos a análises estatísticas. A análise radiográfica demonstrou maior área radiolúcida no interior do defeito ósseo para o grupo experimental, nos períodos de 14 (p=0,016), 30 (p=0,009) e 90 (p=0,028) dias. Na análise histológica não se observaram atrasos no processo de reparo ósseo para ambos os grupos. Porém, na análise histomorfométrica, o grupo da amlodipina apresentou redução significante do volume de osso neoformado nos períodos de 7 e 14 dias (p=0,049), não havendo diferenças significativas no período de 30 dias. Houve redução significante nos níveis de fosfatase alcalina para o grupo da amlodipina nos períodos iniciais (p=0,049). Não houve alterações para os níveis de cálcio sérico. Concluiu-se que o uso crônico da amlodipina prejudicou a neoformação óssea no processo de reparo do defeito cirúrgico no ramo mandibular de ratos, porém não impediu a consolidação da fratura. / Antihypertensive, calcium channel blockers, which interfere on calcium transport across the cell membrane, may affect many metabolic processes, including bone metabolism. The aim of this study was to evaluate by radiographic, histologic and biochemical analyses the effects of calcium channel blocker amlodipine on bone healing of a defect simulating a fracture in mandibular ramus of rats. Fifty male Wistar rats were used, and submitted to the same unilateral surgical procedure simulating a mandibular fracture, distributed into two groups of 25 animals: experimental group, which received oral doses of 0.04 mg / rat / day starting 12 days before of procedure and continuing until sacrifice; control group, which remained untreated. Animals were sacrificed at 1, 7, 14, 30 and 90 days postoperatively. Blood biochemical tests of alkaline phosphatase and serum calcium were made. Radiographic examination was obtained in order to mensurate the radiolucent area of bone defect. Histological study comprised descriptive analysis of bone healing and histomorphometric analysis of the amount of newly formed bone. Numerical values were submitted to statistical analyses. Radiographic analysis showed larger radiolucent area into bone defect to the experimental group at the periods of 14 (p=0.016), 30 (p=0.009) and 90 (p=0.028) days. In the histological analysis there was no delay in the bone repair stages in both groups. However, in the histomorphometric analysis, the experimental group presented significative lowering of newly formed bone volume at 7 and 14 days periods (p=0.049), with no significant differences at 30 days period. There was significative decrease of alkaline phosphatase levels in experimental group in the initial periods (p=0.049). There was no change in the serum calcium levels. It was concluded that chronic use of amlodipine compromised bone neoformation in the repairing process of surgical defect in the mandibular ramus of rats, but no precluded occurrence of fracture consolidation.
|
20 |
Retrospective analysis of the prescribing patterns of calcium channel blockers in a section of the private health care sector of South Africa / Ruan SmitSmit, Ruan January 2010 (has links)
Background: Calcium channel blockers are mainly divided into antihypertensive and antianginal
treatment agents. In 2000 it was estimated that 972 million adults worldwide were
living with hypertension and it is expected to affect 1.56 billion patients by 2025. The
incremental expenditure for the antihypertensive therapeutic group in the United States of
America was estimated at $US 55 billion per annum in 2006.
It was stated that around seven million people in the United States of America suffered from
angina, with around 400 000 new reports every year.
Objective: To determine the prescribing patterns of calcium channel blocker medicine items
during 2005 to 2008 in a section of the private health care sector of South Africa.
Methods: A retrospective quantitative drug utilisation review was done using a medicine
claims database ranging over four years from 1 January 2005 to 31 December 2008. The
total medicine claims database was divided into cardiovascular medicine items and then into
calcium channel blockers. These were analysed according to age as well as gender. Further
analysis included adherence of calcium channel blockers as well as an analysis of
prescribers of these items during the study period.
Results: The total number of patients on the medicine claims database consisted of
1 509 621 patients in 2005. This number decreased to 974 497 patients in 2008. The most
medicine items were dispensed in 2006 (n = 21 113 422) with an average cost of
R 92.82 (SD = 196.42) per medicine item.
It was noted that 16.05% (n = 242 264) of patients used at least one cardiovascular item in
2005. The percentage of cardiovascular medicine item users increased by 4.36% during the
study period to 20.41% (n = 198 847) in 2008. In 2008 the cardiovascular medicine items
dispensed were responsible for 19.18% (R 342 565 308.41) of the total cost of all medicine
items claimed.
In 2005 the results revealed that 1.63% (n = 318 258) of all medicine items dispensed were
calcium channel blocker medicine items. The percentage of calcium channel blockers
increased to 2.24% (n = 367 437) of the total number of medicine items in 2008. The cost
prevalence index was calculated for the calcium channel blockers and the value declined
from 1.5 in 2005 to 1.22 in 2008, which indicated that the items dispensed were relatively
expensive, but less than in 2005. An increase of 16.17% in the usage of generic medicine
items were noted from 2005 to 2008.
More female patients than male patients claimed medicine items during the study period. A
higher percentage of male patients used a cardiovascular medicine item as well as calcium
channel blockers during the study period compared to females and a larger percentage of
their medicine expenditure was used on cardiovascular medicine items as well as calcium
channel blockers compared to females.
The usage of cardiovascular medicine items as well as calcium channel blocker medicine
items increased with patient age. In 2008, 17.98% of patients older than 65 years of age
used a calcium channel blocker compared to 0.97% of patients aged > 25 <= 35 years. Only
60.34% of calcium channel blockers items were used with acceptable refill adherence rates
during the study. More than a third of the calcium channel blockers medicine items used had
unacceptable low adherence rates from 2005 to 2008.
In each of the study years the highest potential saving with generic substitution was seen
with amlodipine containing items. It was also observed that some generic substitutions could
be relatively more expensive than the innovator products and an increased cost instead of a
saving through generic substitution may have occurred.
Conclusion: This study highlighted the prescribing patterns and cost implications of calcium
channel blockers in the private health care sector of South Africa.
It is recommended that a more in–depth study of the adherence of calcium channel blockers
be done. This study should also include the cost strategies of generic substitution of calcium
channel blockers in South Africa. / Thesis (M.Pharm (Pharmacy Practice))--North-West University, Potchefstroom Campus, 2011.
|
Page generated in 0.1108 seconds